Invasive pneumococcal disease

Invasive pneumococcal disease is a serious infection caused by Streptococcus pneumoniae, also known as pneumococci ^[1]. The provided sources characterize it as part of the broader spectrum of pneumococcal disease and note that it includes severe invasive illness rather than only localized respiratory infection ^[1][2]. The catalogue payload does not provide additional source-backed detail on formal case definitions, anatomic thresholds for invasiveness, or ICD coding ^[3][4][5].

The sources identify pneumonia, with or without septicaemia, and meningitis as major severe manifestations associated with pneumococcal infection, while otitis and sinusitis are described as milder respiratory tract infections ^[1]. They also state that IPD is a severe invasive outcome, and that incidence has fallen in vaccinated children in settings using childhood pneumococcal conjugate vaccination ^[1][2]. Non-vaccine serotypes have been reported to cause IPD in unvaccinated populations, including older adults, and type 3 is noted as a persistent challenge in several countries ^[1][2]. Source-backed detail on symptom sequence, complications beyond the listed syndromes, and prognostic course is not yet available ^[1][2].

The sources indicate that pneumococcal infections remain an important public-health problem and that severe IPD has decreased in vaccinated children after introduction of childhood conjugate vaccination programs in many countries ^[1]. At the same time, non-vaccine types have increased and have been associated with IPD in unvaccinated populations such as older adults, which has limited the overall impact of vaccination on disease burden ^[1]. The literature also notes that multivalent conjugate vaccines of increasing valency have been licensed over the last 22 years and that serotype-specific challenges continue, including type 3 in several countries ^[2]. Beyond these broad patterns, source-backed detail on geographic distribution, outbreak behavior, or surveillance counts is not yet available ^[1][2].

The supplied sources do not provide a direct description of transmission route, person-to-person spread, or exposure mechanism for invasive pneumococcal disease ^[1][2]. They do, however, frame the disease as caused by Streptococcus pneumoniae and emphasize serotype dynamics in the context of vaccination and disease emergence ^[1][2]. Source-backed detail on persistence, environmental reservoirs, or specific transmission settings is not yet available ^[1][2].

The clearest source-backed risk group mentioned is unvaccinated populations, including older adults, among whom non-vaccine pneumococcal types have caused IPD ^[1]. Vaccinated children are also referenced as a group in whom severe disease decreased after childhood conjugate vaccination programs, underscoring the relevance of vaccine status to risk interpretation ^[1]. Beyond these groups, the provided sources do not supply additional source-backed detail on host factors, comorbidities, or occupational exposures ^[1][2].

Prevention in the source material centers on pneumococcal vaccination, including pneumococcal conjugate vaccines, which are described as pivotal in reducing IPD incidence ^[1][2]. The abstracts also note that newer PCV15 and PCV20 vaccines have been licensed for U.S. adults on the basis of safety and immunogenicity data, and that vaccine impact may be complicated by non-vaccine serotypes ^[6][1]. Emerging antibiotic resistance is also identified as a threat to effective control, but the provided sources do not describe specific non-vaccine preventive measures or schedules ^[1].

In surveillance, IPD should be read as a severe, vaccine-relevant pneumococcal outcome whose trend can change with vaccination coverage, serotype replacement, and age-specific susceptibility ^[1][2]. The sources indicate that reductions in vaccinated children may coexist with continued disease in unvaccinated groups, including older adults, so burden should be interpreted by age and vaccine-era context ^[1]. Because the payload contains only summary evidence, source-backed detail on notification criteria, laboratory confirmation standards, or reporting frequency is not yet available ^[3][4][5][1].

1. 1 Narciso AR et al. Streptococcus pneumoniae epidemiology, pathogenesis and control. Nat Rev Microbiol. 2025 Apr. PMID: 39506137. doi: 10.1038/s41579-024-01116-z. PubMed: https://pubmed.ncbi.nlm.nih.gov/39506137/
2. 2 Micoli F et al. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj J. 2023 Apr. PMID: 36652051. doi: 10.1007/s10719-023-10100-3. PubMed: https://pubmed.ncbi.nlm.nih.gov/36652051/
3. 3 Invasive pneumococcal disease. New South Wales Public Health Bulletin. 2013. doi: 10.1071/nb12117. DOI: https://doi.org/10.1071/nb12117
4. 4 Invasive pneumococcal disease. Archives of disease in childhood - Education & practice edition. 2011. doi: 10.1136/adc.2010.191718. DOI: https://doi.org/10.1136/adc.2010.191718
5. 5 Invasive Pneumococcal Disease and Pneumococcal Pneumonia. Clinical Pulmonary Medicine. 2014. doi: 10.1097/cpm.0000000000000029. DOI: https://doi.org/10.1097/cpm.0000000000000029
6. 6 Farrar JL et al. Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults. Pathogens. 2023 May 19. PMID: 37242402. doi: 10.3390/pathogens12050732. PubMed: https://pubmed.ncbi.nlm.nih.gov/37242402/

ICD-10

ICD-11

Total cases

196K

Peak month

2018-01

Coverage

8 reporting countries · 2000-01-01 → 2026-06-20